Program
Pramipexole
Also written as “pramipexole”, “Pramipexole Dihydrochloride” and “Pramipexole Immediate Release”.
Its studies are mostly in Parkinson Disease · Restless Legs Syndrome · Tourette Syndrome · Depressive Disorder, Major · Obsessive-Compulsive Disorder, led by 6 companies.
Drug pagePramipexole: every studyMany companies study it; this page follows only the 43 they lead. All 81 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 360 open or running | phase 4since Sep 2, 2005 | Aug 22, 2005 | none ahead |
| Teva Pharmaceutical Industriesits history only | 30 open or running | phase 4since Nov 10, 2006 | Nov 10, 2006 | none ahead |
| Chase Therapeutics | 11 open or running | phase 2since Jul 5, 2018 | Jul 5, 2018 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since May 8, 2007 | May 8, 2007 | none ahead |
| Haisco Pharmaceutical Groupits history only | 10 open or running | phase 1since Apr 2, 2026 | Apr 2, 2026 | none ahead |
| Novartisits history only | 10 open or running | phase 4since Aug 23, 2012 | Aug 23, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chase Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 5, 2018First study: phase 2 study in Depressive Disorder, MajorFirst studyNCT03642964 · 24 enrolled · United States
TargetBeta
“D2-like dopamine receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| rotigotinerule | UCB | phase 4 | 64 |
Studies
The one study Chase Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03642964Depressive Disorder, Major · United States | 2 | Active, not recruiting | Dec 30, 2025 | 24 |
How it is read
Names in the registry
- “Pramipexole”, 15 entries
- “pramipexole”, 5 entries
- “Pramipexole Dihydrochloride”, 4 entries
- “Pramipexole Immediate Release”, 2 entries
- “Pramipexole Extended Release”, 2 entries
Conditions, from the studies’ own filings
- Parkinson Disease, 19 studies
- Restless Legs Syndrome, 12 studies
- Tourette Syndrome, 2 studies
- Depressive Disorder, Major, 1 study
- Obsessive-Compulsive Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.